Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide for treatment-refractory lupus-associated skin lesions in systemic lupus erythematosus
ChiCTR1900025376Phase 4Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of lenalidomide in systemic lupus erythematosus (SLE) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index activity score at month 6 and Systemic Lupus Erythematosus Disease Activity Index at month 6. Started Sep 2019; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR1900025376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025376.